<DOC>
	<DOC>NCT02110082</DOC>
	<brief_summary>The purpose of the study is to determine the safety, tolerability and maximum tolerated dose of Urelumab in combination with Cetuximab in patients with Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck.</brief_summary>
	<brief_title>Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Subjects with advanced/metastatic Colorectal Cancer(CRC) who have failed or been intolerant to both irinotecan and oxaliplatin based regimens Subjects with advanced/metastatic Squamous cell carcinoma of the head and neck (SCCHN) who are without options for curative treatment Subjects must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria Men and women 18 and older Women of childbearing potential (WOCBP) and men must use highly effective methods of contraception Eastern Cooperative Oncology Group (ECOG) of 0 or 1 Subjects must have a life expectancy of at least 3 months Active or progressing brain metastases Other concomitant malignancies (with some exceptions per protocol) Nasopharyngeal carcinoma Active or history of autoimmune disease Positive test for Human Immunodeficiency Virus (HIV) 1&amp;2 or known AIDS History of any hepatitis (A,B or C) Known current drug or alcohol abuse Active Tuberculosis (TB) Use of anticancer treatments within 28 days Prior therapy with antiCD137 antibody Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>